Fulcrum Therapeutics (NASDAQ:FULC) Receives New Coverage from Analysts at Bank of America

Bank of America began coverage on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a report issued on Monday morning, 24/7 WallStreet reports. The firm issued a buy rating and a $19.00 target price on the stock.

NASDAQ:FULC traded up $0.25 during trading hours on Monday, reaching $11.40. The company had a trading volume of 5 shares, compared to its average volume of 81,711. Fulcrum Therapeutics has a one year low of $10.99 and a one year high of $15.94.

In other Fulcrum Therapeutics news, Director Mark J. Levin acquired 81,250 shares of Fulcrum Therapeutics stock in a transaction on Monday, July 22nd. The shares were bought at an average price of $16.00 per share, with a total value of $1,300,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder 6 Dimensions Capital, L.P. acquired 118,750 shares of Fulcrum Therapeutics stock in a transaction on Monday, July 22nd. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $1,900,000.00. The disclosure for this purchase can be found here.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia.

Recommended Story: How to track put option volume

Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.